Aurinia Pharmaceuticals (AUPH) vs Mineralys Therapeutics (MLYS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Aurinia Pharmaceuticals (AUPH) has outperformed Mineralys Therapeutics (MLYS) over the past year, gaining 40.7% versus a loss of 40.3%. Aurinia Pharmaceuticals is the larger company by market cap ($2.16 billion vs $1.98 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AUPH | MLYS |
|---|---|---|
| Share price | $16.22 | $22.38 |
| Market cap | $2.16B | $1.98B |
| 1-day change | +1.31% | +1.31% |
| YTD return | +1.69% | -38.33% |
| 1-year return | +40.68% | -40.30% |
| 5-year return | -21.15% | — |
| P/E ratio (TTM) | 7.11 | — |
| Forward P/E | 15.21 | — |
| EPS (TTM) | $2.28 | $-4.22 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $283.06M | — |
| Revenue growth (YoY) | +20.38% | — |
| Net income (latest FY) | $287.20M | $-154.65M |
| Gross margin | 88.46% | — |
| Operating margin | 37.06% | — |
| Net margin | 101.47% | — |
| 52-week high | $19.25 | $47.65 |
| 52-week low | $10.90 | $21.46 |
| Distance from 52-week high | -15.74% | -53.03% |
| Analyst consensus | none | none |
| Avg. price target upside | +10.11% | +116.71% |
| Average volume | 988.90K | 1.03M |
| Shares outstanding | 133.05M | 88.41M |
| Employees | 128 | 76 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AUPH has outperformed MLYS by 81.0 percentage points over the past year.
About Aurinia Pharmaceuticals
AUPH stock →Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis.
Health Care · Biotechnology: Pharmaceutical Preparations · 128 employees
About Mineralys Therapeutics
MLYS stock →Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea.
Health Care · Biotechnology: Pharmaceutical Preparations · 76 employees
AUPH vs MLYS FAQ
Which is bigger, Aurinia Pharmaceuticals or Mineralys Therapeutics?
Aurinia Pharmaceuticals (AUPH) is larger, with a market capitalization of $2.16B compared with $1.98B for Mineralys Therapeutics (MLYS).
Which stock has performed better over the past year, AUPH or MLYS?
AUPH returned +40.68% over the past 12 months, compared with -40.30% for MLYS (price return, excluding dividends). Past performance does not predict future results.
Are Aurinia Pharmaceuticals and Mineralys Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.